Uncertainty in drug development: Approval success rates for new drugs

Clinical Drug Trials and Tribulations: Second Edition, Revised and Expanded

Volumn , Issue , 2002, Pages 328-346

  DiMasi, Joseph A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57349166090     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (17)

1. Wardell WM, Hassar M, Anavekar SN, and Lasagna L. The rate of development of new drugs in the United States 1963 through 1975. Clin Pharmacol Ther 1978; 24:133-145.
2. Wardell WM, DiRaddo J, and Trimble AG. Development of new drugs originated and acquired by United States-owned pharmaceutical firms, 1963-76. Clin Pharmacol Ther1980; 28:270-277.
3. Wardell WM, May MS, and Trimble AG. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-79. Clin Pharmacol Ther 1982; 32:407-417.
4. Mattison N, Trimble AG, and Lasagna L. New drug development in the United States, 1963 through 1984, Clin Pharmacol Ther 1988; 43:290-301.
5. DiMasi JA, Bryant NR, and Lasagna L. New drug development in the United States from 1963 to 1990. Clin Pharmacol Ther 1991; 50:471-486.
6. DiMasi JA, Seibring MA, and Lasagna L. New drug development in the United States from 1963 to 1992, Clin Pharmacol Ther 1994; 55:609-622.
7. Pharmaceutical R&D: Costs, Risks, and Rewards. (OTA-H-522). Washington, DC: U.S. Congress, Office of Technology Assessment, 1993.
8. Gosse ME, DiMasi JA, and Nelson TF. Recombinant proteins and therapeutic monoclonal antibody drug development in the United States: 1980-1994. Clin Pharmacol Ther, 1996; 60:608-618.
9. Tucker SA, Blozan C, and Coppinger P. The Outcome of Research on New Molecular Entities Commencing Clinical Research in the Years 1976-78.(OPE Study 77). Rockville, MD: Food and Drug Administration, 1988.
10. B Bienz-Tadmor, DiCerbo PA, Tadmor G, and Lasagna L. Biopharmaceuticals and conventional drugs: clinical success rates. Bio/Technology 1992; 10:521-525.
11. Struck MM. Biopharmaceutical R&D success rates and development times. Bio/Technology 1994; 12:674-677.
12. DiMasi JA, Hansen RW, Grabowski HG, and Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10:107-142.
13. DiMasi JA, Hansen RW, Grabowski HG, and Lasagna L. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. PharmacoEconomics 1995; 7:152-169.
14. DiMasi JA, Grabowski HG, and Vernon J. R&D costs, innovative output, and firm size in the pharmaceutical industry. Int J Econ Business. 1995; 2:201-219.
15. Cox C. A statistical analysis of the success rates and residence times for the IND, NDA and combined phases. In: Lasagna L, Wardell WM, Hansen RW, eds.Technological Innovation and Government Regulation of Pharmaceuticals in the United States and Great Britain.Washington, DC: National Science Foundation, 1978.
16. Sheck L, Cox C, Davis HT, Trimble AG, Wardell WM, and Hansen RW. Success rates in the United States drug-development system. Clin Pharmacol Ther 1984; 36: 574-583.
17. DiMasi JA, Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther. 1995; 58:1-14.